This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
MAP4K5 · Western blot design guide
MAP4K5 Western Blot Planning Guide
Plan a MAP4K5 Western blot around the catalog-observed 95.1 kDa band, image-backed A10186-1 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
MAP4K5 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 95.1 kDa observed | |
| Observed band | 95.1 kDa observed | |
| Gel | 8-10% | |
| Positive control | Colon | |
| Negative control | Bronchus |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 95.1 kDa |
| ⓘ | Localization | Cytoplasm |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human |
Section 1
Real Curated MAP4K5 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Cerebellum |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | A10186-1 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 2
What Is the Expected MAP4K5 Western Blot Band Size?
Use the product-observed 95.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 95.1 kDa | Matches the authoritative product WB observation. |
| 95.1 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected MAP4K5 appearancePlan around 95.1 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 95.1 kDa; use this as the primary experimental expectation. |
| Calculated mass | 95.1 kDa from UniProt Q9Y4K4; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with A10186-1. |
| Situation | Likely cause | Next action |
|---|---|---|
| 95.1 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing MAP4K5 band
A10186-1 · MAP4K5
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Sample controls for MAP4K5 Western blot
🧪Use Colon as the first positive-control candidate and retain an orthogonal negative control.
Positive control: Colon (Medium)
Negative control: Bronchus (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for MAP4K5
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Colon | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Cerebellum | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Esophagus | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Duodenum | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 3
Advanced MAP4K5 Western Blot Tips
Deeper troubleshooting and optimisation questions for MAP4K5, answered from its protein features.
Which band should guide the blot?
Use 95.1 kDa, the observation attached to the authoritative A10186-1 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 95.1 kDa expectation.
Which positive control should I start with?
Start with Colon, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bronchus as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for MAP4K5 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should A10186-1 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents
MAP4K5 Western Blot Reagents
Human-reactive MAP4K5 Western blot reagents with authoritative product imagery.
Real WB data
Anti-MAP4K5 Antibody Picoband®
Cat # A10186-1
Real WB data
Anti-MAP4K5 Antibody Picoband®
Cat # A10186-2
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt Q9Y4K4
- Human Protein Atlas — MAP4K5
- A10186-1 product record
- PMC4741478 — Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening (Oncotarget, 2015)
- PMC4811546 — Prognostic and Functional Significance of MAP4K5 in Pancreatic Cancer (PloS one, 2016)
- PMC9998968 — Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition (The Journal of experimental medicine, 2023)